| abstract |
The invention relates to in vitro methods of distinguishing, in a patient diagnosed with an ovarian tumour, between a benign ovarian cyst and malignant ovarian cancer, based on determining in a blood sample the amount of at least NK cells, total myeloid cells, myeloid-derived suppressor cells (MDSC), monocytic myeloid derived suppressor cells (mMDSC), and PDL1 positive monocytic myeloid derived suppressor cells (mMDSC-PDL1). The invention further relates to kits comprising reagents for the detection of NK cells, myeloid-derived suppressor cells (MDSC), monocytic myeloid derived suppressor cells (mMDSC), and PDL1 positive monocytic myeloid derived suppressor cells (mMDSC-PDL1). |